China Capmatinib Hydrochloride Hydrate Manufacturers Factory Suppliers
Our high-quality api providers, api monitoring, api integrations with cms and attentive service have won the trust and praise of many consumers and established a good brand. Our unique modular design optimizes the product structure and ensures the long-term stable and reliable operation of the Capmatinib Hydrochloride Hydrate. We are committed to creating a community of destiny with all our customers and tightening the bonds of mutual interests. Our company is committed to reducing our environmental impact, implementing sustainable practices and initiatives across all aspects of our operations. Looking forward to the future, we firmly believe that we will continue to move forward with scientific strategic planning and meticulous and forward-looking R&D innovation. We hope to lead industrial upgrading and transformation with innovation-driven and technological progress, and therefore actively promote the talent development strategy. Our products are designed to be both innovative and practical, ensuring that our clients have access to the best possible technology and functionality available. We are dedicated to providing our clients with the best possible service and support, no matter how challenging their requirements.Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling...
Capmatinib Hydrochloride Hydrate (capmatinib) is a low molecular compound discovered by Incyte (the US). Capmatinib is expected to exhibit anti-tumor activity in non-small cell lung...
D10891 Capmatinib hydrochloride (USAN)
Capmatinib hydrochloride is approved to treat: Non-small cell lung cancer that has a certain mutation in the MET gene. It is used in adults whose cancer has spread to other parts of the...
Capmatinib Hydrochloride is the hydrochloride salt form of capmatinib, an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with...
TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial...
